← Back to Search

Monoclonal Antibodies

Participants receiving mepolizumab + Standard of care (SoC) for Nasal Polyp Size (MERIT Trial)

Phase 3
Waitlist Available
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 52 weeks
Awards & highlights
Pivotal Trial

Summary

This is a randomized, double blind, placebo controlled, parallel group phase III study designed to assess the clinical efficacy and safety of 100 milligrams (mg) subcutaneous (SC) mepolizumab treatment in adults with CRSwNP/ECRS for the purpose of registration in Japan and China. Approximately 160 participants will be randomized in a 1:1 ratio to receive either 100 mg SC mepolizumab or placebo SC. The study will include a 4-week run-in period followed by randomization to a 52-week treatment period, where participants will be administered 4-weekly doses of mepolizumab or placebo via a pre-filled safety syringe device (SSD) injection.

Eligible Conditions
  • Nasal Polyp Size
  • Nasal Polyps

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline in mean nasal obstruction visual analogue scale (VAS) score (scores on a scale)
Change from Baseline in total endoscopic NP score at Week 52 (scores on a scale)
Secondary study objectives
Change from Baseline in Lund Mackay (LMK) computed tomography (CT) score at Week 52 (scores on a scale)
Anosmia
Change from Baseline in mean overall VAS symptom score (scores on a scale)
+3 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Participants receiving mepolizumab + Standard of care (SoC)Experimental Treatment2 Interventions
Participants will receive one dose of 100 mg mepolizumab SC on top of SoC every 4 weeks during the 52-week treatment period.
Group II: Participants receiving placebo + SoCPlacebo Group2 Interventions
Participants will receive one dose of placebo via SC route on top of SoC, every 4 weeks during the 52-week treatment period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Standard of care
2020
Completed Phase 4
~17710
Mepolizumab
2020
Completed Phase 4
~5010

Find a Location

Who is running the clinical trial?

Signant HealthUNKNOWN
GlaxoSmithKlineLead Sponsor
4,805 Previous Clinical Trials
8,379,333 Total Patients Enrolled
BioClinica, Inc.Industry Sponsor
7 Previous Clinical Trials
2,849 Total Patients Enrolled
~36 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top